NO20003179L - Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat - Google Patents

Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat

Info

Publication number
NO20003179L
NO20003179L NO20003179A NO20003179A NO20003179L NO 20003179 L NO20003179 L NO 20003179L NO 20003179 A NO20003179 A NO 20003179A NO 20003179 A NO20003179 A NO 20003179A NO 20003179 L NO20003179 L NO 20003179L
Authority
NO
Norway
Prior art keywords
optionally substituted
pharmaceutical composition
ring
anilide derivative
antagonizing ccr5
Prior art date
Application number
NO20003179A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003179D0 (no
Inventor
Osamu Nishimura
Masanori Baba
Hidekazu Sawada
Naoyuki Kanzaki
Ken-Ichi Kuroshima
Mitsuru Shiraishi
Yoshio Aramaki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20003179D0 publication Critical patent/NO20003179D0/no
Publication of NO20003179L publication Critical patent/NO20003179L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20003179A 1997-12-19 2000-06-19 Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat NO20003179L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP35148097 1997-12-19
JP21887598 1998-08-03
JP23438898 1998-08-20
PCT/JP1998/005708 WO1999032100A2 (fr) 1997-12-19 1998-12-17 Composition pharmaceutique antagoniste de ccr5 et contenant un derive d'anilide

Publications (2)

Publication Number Publication Date
NO20003179D0 NO20003179D0 (no) 2000-06-19
NO20003179L true NO20003179L (no) 2000-06-19

Family

ID=27330200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003179A NO20003179L (no) 1997-12-19 2000-06-19 Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat

Country Status (12)

Country Link
US (2) US6172061B1 (fr)
EP (1) EP1039899A2 (fr)
JP (1) JP2000128782A (fr)
KR (1) KR20010032841A (fr)
CN (1) CN1282243A (fr)
AU (1) AU748064B2 (fr)
BR (1) BR9813691A (fr)
CA (1) CA2304959A1 (fr)
HU (1) HUP0100199A2 (fr)
ID (1) ID29994A (fr)
NO (1) NO20003179L (fr)
WO (1) WO1999032100A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
FR2746101B1 (fr) * 1996-03-14 1998-04-30 Composes bicycliques-aromatiques
JP2002521441A (ja) * 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Ｃｃｒ５モジュレーターとしてのプロペンアミド
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
WO2000021916A1 (fr) * 1998-10-15 2000-04-20 Takeda Chemical Industries, Ltd. Procede de preparation de derives d'amine
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
WO2000037455A1 (fr) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Derives de benzothiepin-anilide, production et utilisation comme antagoniste de ccr-5
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2000056729A1 (fr) 1999-03-24 2000-09-28 Anormed Inc. Composes heterocycliques se liant aux recepteurs de chimiokine
WO2000068203A1 (fr) * 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Composes cycliques et leurs utilisations
AU4777500A (en) 1999-05-18 2000-12-05 Takeda Chemical Industries Ltd. Processes for the preparation of 2,3-dihydrothiepine derivatives
CA2380860A1 (fr) * 1999-06-16 2000-12-21 Takeda Chemical Industries, Ltd. Derives de benzazepine, procede de preparation et d'utilisation
AU6870500A (en) * 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine derivatives
EP1211239A4 (fr) * 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd Procedes de preparation de composes 2,3-dihydroazepine
WO2001021832A1 (fr) * 1999-09-23 2001-03-29 Isis Innovation Limited Gene de susceptibilite pour des affections intestinales inflammatoires
US20030078189A1 (en) * 1999-12-10 2003-04-24 Yohko Akiyama Medicinal compositions for oral use
CN1404461A (zh) * 2000-02-21 2003-03-19 武田药品工业株式会社 生产环状化合物的方法
EP1267879A2 (fr) 2000-03-30 2003-01-02 Bristol-Myers Squibb Company Granules a liberation lente contenant de la stavudine
IL154228A0 (en) * 2000-09-15 2003-07-31 Anormed Inc Chemokin receptor binding heterocyclic compounds
WO2002034760A2 (fr) * 2000-10-23 2002-05-02 Smithkline Beecham Corporation Composes et procedes
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
PE20030329A1 (es) * 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
WO2003014110A1 (fr) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Derive de benzazepine, son procede de preparation et d'utilisation
RU2308451C2 (ru) 2001-09-12 2007-10-20 Анормед, Инк. Способы получения рацемического аминозамещенного 5,6,7,8-тетрагидрохинолина или рацемического аминозамещенного 5,6,7,8-тетрагидроизохинолина, способы их разделения и рацемизации, способ получения кетозамещенного 5,6,7,8-тетрагидрохинолина или кетозамещенного 5,6,7,8-тетрагидроизохинолина, способ получения энантиомера конденсированного бициклического кольца, замещенного первичным амином, производные 5,6,7,8-тетрагидрохинолина
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
JP4896518B2 (ja) * 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
US7288654B2 (en) * 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
CN101333185A (zh) * 2003-03-14 2008-12-31 小野药品工业株式会社 含氮杂环衍生物以及包含所述化合物作为活性成分的药物
RU2366655C2 (ru) 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
EP1619193A4 (fr) 2003-04-18 2010-08-11 Ono Pharmaceutical Co Compose de spiropiperidine et son utilisation medicinale
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
BRPI0512623A (pt) * 2004-06-25 2008-03-25 Janssen Phamaceutica N V sal quaternário antagonista de ccr2
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
WO2006129679A1 (fr) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. Compose de spiropiperidine et son utilisation medicinale
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
CA2644368A1 (fr) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif
US20090186817A1 (en) * 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
WO2007132846A1 (fr) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. Composé ayant un groupe acide qui peut être protégé et utilisation dudit composé
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
PE20081785A1 (es) * 2007-02-19 2009-01-12 Novartis Ag Derivados de ciclohexil-amida del acido aril carboxilico
US8168829B2 (en) * 2007-10-26 2012-05-01 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
US8093428B2 (en) * 2007-10-26 2012-01-10 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
CN101481323B (zh) * 2008-01-11 2013-11-20 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
CN102796075B (zh) * 2008-01-11 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
WO2010054215A1 (fr) * 2008-11-06 2010-05-14 Ventirx Pharmaceuticals, Inc. Procédés de synthèse de dérivés de benzazépine
WO2010129351A1 (fr) 2009-04-28 2010-11-11 Schepens Eye Research Institute Procédé pour identifier et pour traiter une dégénérescence maculaire liée à l'âge
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
WO2016019587A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés antidiabétiques bicycliques condensés [7, 6]
CA2971093A1 (fr) 2014-12-23 2016-06-30 Tobira Therapeutics, Inc. Procede de preparation de cenicriviroc et d'analogues apparentes
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389634B1 (fr) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
CA3019394A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methodes de traitement du cancer
US10407411B2 (en) 2016-06-21 2019-09-10 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3808748A1 (fr) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Piperidines substutues comme inhibiteurs de cxcr4
EP3472129A4 (fr) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
WO2018045043A1 (fr) 2016-08-31 2018-03-08 Tobira Therapeutics, Inc. Formes solides de mésylate de cenicriviroc et procédés de fabrication de formes solides de mésylate de cenicriviroc
ES2906992T3 (es) * 2016-12-09 2022-04-21 Medshine Discovery Inc Compuesto de bifenilo como antagonista del receptor CCR2/CCR5
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021165960A1 (fr) 2020-02-19 2021-08-26 Ichilov Tech Ltd. Traitement par antidépresseur amélioré
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN113735904B (zh) * 2021-09-17 2023-10-24 南京自一界科技研发有限公司 一种润滑添加剂的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199721T1 (de) * 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd Phosphonsäure verbindungen imre herstellung und verwendung
KR20010032643A (ko) * 1997-12-19 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 아닐리드 유도체, 그의 제조 및 용도

Also Published As

Publication number Publication date
WO1999032100A2 (fr) 1999-07-01
CN1282243A (zh) 2001-01-31
WO1999032100A3 (fr) 1999-09-10
ID29994A (id) 2001-10-25
AU748064B2 (en) 2002-05-30
HUP0100199A2 (hu) 2001-04-28
US6172061B1 (en) 2001-01-09
BR9813691A (pt) 2000-10-10
AU1683199A (en) 1999-07-12
US6268354B1 (en) 2001-07-31
CA2304959A1 (fr) 1999-07-01
NO20003179D0 (no) 2000-06-19
EP1039899A2 (fr) 2000-10-04
KR20010032841A (ko) 2001-04-25
JP2000128782A (ja) 2000-05-09

Similar Documents

Publication Publication Date Title
NO20003179L (no) Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat
NO20003133L (no) Anilid-derivat, fremstilling og anvendelse derav
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
NO307047B1 (no) Nye hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere, farmasøytisk preparat inneholdende slike, og anvendelse derav
NO932620L (no) Amindiol-proteaseinhibitorer
NO970512L (no) Nye heteroaryl-oksazolidinoner
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
MXPA02012314A (es) Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos.
AP9701041A0 (en) Pyridylpyrrole compounds.
DK0650961T3 (da) Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
NO180583C (no) Arylsulfonamido-substituerte hydroksamsyrer, farmasöytiske preparater inneholdende forbindelsene og anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
TR199800924T2 (xx) Quinoline t�revleri.
CA2119647A1 (fr) Amines heteroaryliques comme nouveaux inhibiteurs de l'acetylcholinesterase
CA2093077A1 (fr) Derives amino ou azido en 2 ou en 3 de 1,5-iminosucres
DE69427517D1 (de) Tetracyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
CA2093076A1 (fr) Derives amino ou azido en 2 ou en 3 de 1,5-iminosucres
DK492288D0 (da) Amidforbindelser, farmaceutisk praeparat indeholdende samme samt fremgangsmaade til fremstilling af forbindelserne
YU69699A (sh) Derivati aril karbonske kiseline i tetrazola
MX9707461A (es) Heterociclos nitrogenados de ciclohexilamino y ciclohexilalcoxi, metodos para preparar los mismos y su uso como agentes de control de pestes y fungicidas.
NO961168D0 (no) Nye uretanholdige aminosteroid forbindelser
EP1283208A4 (fr) Nouveaux derives de benzofurane
NO984921L (no) Tienopyridinderivater og deres anvendelser
EP0369743A3 (fr) Amides hétérocycliques
DK0736009T3 (da) N-oxider af 4-arylpiperaziner og 4-arylpiperidiner som antipsykotiske medikamenter
NO911237L (no) Fremgangsmaate for fremstilling av hydroxymethyl-indolizidiner og kinolizidiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application